Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
Related Stories
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 27 days
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 27 days
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 29 days
Common asthma drug may overcome immunotherapy resistance in cancers / 5 wks
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 5 wks
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 2 months
James P. Allison wins AACR lifetime achievement award / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Venture Capital, Cybersecurity, Hospital Operations, Biotech and look for the RSS link.
StackHealth Time Machine